Misplaced Pages

Alsactide

Clinical data
ATC code	V04CH04 (WHO)
Identifiers
CAS Number	34765-96-3
PubChem CID	16129705
ChemSpider	17286506
UNII	J0K70H3420
KEGG	D07417
CompTox Dashboard (EPA)	DTXSID90188321
ECHA InfoCard	100.047.442
Chemical and physical data
Formula	C99H155N29O21S
Molar mass	2119.57 g·mol
3D model (JSmol)	Interactive image
SMILES /N=C(\N)/NCCC(C(=O)N(Cc1cc2c1cccc2)C(=O)NCC(=O)N(CCCCN)C(=O)N3CCC3C(=O)N(C(C)C)C(=O)NCC(=O)N(CCCCN)C(=O)N(CCCCN)C(=O)N(CCCCN)C(=O)NCCCCN)NC(=O)(Cc4ccccc4)NC(=O)(Cc5cnc5)NC(=O)(CCC(=O)O)NC(=O)(CCSC)NC(=O)(CO)NC(=O)(Cc6ccc(cc6)O)NC(=O)CCN
InChI InChI=1S/C99H155N29O21S/c1-59(2)84(97(148)113-56-81(132)115-68(26-10-14-40-101)87(138)119-69(27-11-15-41-102)88(139)118-67(25-9-13-39-100)85(136)109-45-18-17-43-104)127-96(147)79-30-20-47-128(79)98(149)73(28-12-16-42-103)116-82(133)55-112-86(137)76(51-62-53-111-66-24-8-7-23-65(62)66)124-89(140)70(29-19-46-110-99(106)107)120-93(144)75(49-60-21-5-4-6-22-60)123-94(145)77(52-63-54-108-58-114-63)125-90(141)71(35-36-83(134)135)121-91(142)72(38-48-150-3)122-95(146)78(57-129)126-92(143)74(117-80(131)37-44-105)50-61-31-33-64(130)34-32-61/h4-8,21-24,31-34,53-54,58-59,67-79,84,111,129-130H,9-20,25-30,35-52,55-57,100-105H2,1-3H3,(H,108,114)(H,109,136)(H,112,137)(H,113,148)(H,115,132)(H,116,133)(H,117,131)(H,118,139)(H,119,138)(H,120,144)(H,121,142)(H,122,146)(H,123,145)(H,124,140)(H,125,141)(H,126,143)(H,127,147)(H,134,135)(H4,106,107,110)/t67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,84-/m0/s1 Key:DIDCGVRALANKIU-OTEFFYEFSA-N
(verify)

Alsactide (INN) (brand name Synchrodyn 1-17 or simply Synchrodyn, former development code name Hoechst 433), also known as alisactide, is a synthetic peptide and analogue of adrenocorticotropic hormone (ACTH) which is used in Italy as a diagnostic agent in kidney function for adrenal insufficiency. Like ACTH, alsactide is thought to act as a non-selective agonist of the melanocortin receptors, including the ACTH receptor (MC₂R). However, it appears to show a different profile of receptor selectivity relative to ACTH, as it apparently demonstrated no evidence of inhibition of endogenous ACTH in Addison's disease patients.

See also

• Tetracosactide

References

1. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 34–. ISBN 978-1-4757-2085-3.
2. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 33–. ISBN 978-3-88763-075-1.
3. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 12–. ISBN 978-94-011-4439-1.
4. Kontogeorgos G (1 January 2004). Molecular Pathology of the Pituitary. Karger Medical and Scientific Publishers. pp. 66–. ISBN 978-3-8055-7740-3.

• Peptides
• Melanocortin receptor agonists